Cardiac amyloidosis is a rare disease that significantly impacts quality of life. Recent advances in imaging technology and more thorough genetic analyses have revealed it may be more common than previously believed, but new pharmacotherapies have emerged that directly modify disease progression and improve patient outcomes.

This course will help clinicians better recognize the signs and symptoms, interpret diagnostic findings, evaluate emerging treatment options, and establish referral to accelerate treatment for patients with cardiac amyloidosis.

Certified Patient Cases

Test your knowledge and sharpen your diagnostic skills to recognize these life-threatening conditions earlier and bring appropriate treatment to your patients sooner.

 
   

Self-Paced Learning


Dive into this engaging eLearning curriculum to increase recognition and detection of cardiac amyloidosis to accelerate diagnosis and treatment.

 
   

Webinar


Join expert faculty Farooq Sheikh, MD, FACC and Frederick L Ruberg, MD, FACC in this session to forge a new path to detect and diagnose cardiomyopathies and accelerate treatment to improve patient outcomes.

 


  
Click here to see additional Spotlight Topics in the Clinical Spotlight Series

We are grateful to these distinguished Members of the American College of Cardiology who contributed to this collection:

Farooq Sheikh, MD, FACC

Frederick L Ruberg, MD, FACC

Mithun Devraj, MBBS (certified patient case author, not involved in the webinar)

Rida Laeeq, MD (certified patient case author, not involved in the webinar)

Supported by: Akcea Therapeutics, Inc., Alnylam Pharmaceuticals, MyoKardia, and Pfizer, Inc.
Powered By